Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets remain volatile
Tue, 25 Feb 01:30 pm

Indian share markets pared early gains but hovered slightly above the dotted line in the post-noon trading session. Sectoral indices are trading mixed with consumer durables, IT and pharma stocks being the biggest gainers whereas metal, power and oil & gas stocks are trading in the red.

BSE-Sensex is up 7 points and NSE-Nifty is trading 3 points up. BSE Mid Cap is trading 0.3% up and BSE Small Cap index is trading up by 0.1%. The rupee is trading at 61.9 to the US dollar.

Energy stocks are trading mixed with Gujarat Gas and Petronet LNG being the biggest gainers whereas Gas Authority of India Ltd (GAIL) and Gujarat State Petronet are the major losers. As per a leading financial daily, the board of Gujarat Gas has given a go-ahead for the merger of the state-run gas distribution companies with itself. As per the proposal, GSPC Distribution Networks, GSPC Gas, Gujarat Gas Financial Services and Gujarat Gas Trading Co will be merged with Gujarat Gas. The merger is likely to propel the company's valuations. For full year (CY13), the company's net sales grew by 1.5% YoY and the net profits were up by 28.9% YoY with margins at 11.8%, as compared to 9.3% in CY12. Gujarat Gas' stock is currently trading up by 7.9%.

Majority of the pharma stocks are trading in the green with Aurobindo Pharma and Orchid Chemicals being among major gainers whereas Dr. Reddy's Labs and Natco Pharma being among major losers. As per a leading financial daily, Zydus Cadila or Cadila Healthcare has won final approval from US Food & Drug Administration (USFDA) to market Clonidine Hcl injections in 0.1 & 0.5 mg/ml and 10 ml strengths. Clonidine Hcl injections are indicated in combination with opiates for the treatment of severe pain in cancer. Zydus cadila has filed 216 Abbreviated New Drug Applications (ANDA) and has received 90 approvals so far. The topline of Cadila Healthcare registered a healthy 17% YoY growth during the December 2013 quarter driven by strong growth in exports. The US business recorded an impressive growth of 61% YoY during the quarter. The company filed 31 ANDAs during the quarter. Cadila Healthcare's stock is currently up 1.3%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain volatile". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.